iCardiac Technologies, Inc. and Pfizer have into a multiyear research alliance to develop and validate advanced ECG-based cardiac safety biomarkers utilizing the COMPAS technology platform.
The COMPAS technology was developed at the University of Rochester within its Heart Research Follow-Up Program (HRFUP), a premier group of electrocardiology researchers focused on the ventricular repolarization process of the heart, and exclusively licensed to iCardiac.